Table 6.
Adjusted RRs of inpatient and non-inpatient CDI incidence associated with rates of pre-defined high-risk antibiotic groups
| Inpatient CDI incidence |
Non-inpatient CDI incidence |
|||
|---|---|---|---|---|
| log items per 1000 | RR (95% CI) | P value | RR (95% CI) | P value |
| Co-amoxiclav | 1.0768 (0.9804–1.1834) | 0.124 | 1.0785 (0.9546–1.2197) | 0.230 |
| Cephalosporins | 1.0634 (0.9700–1.1665) | 0.189 | 1.0655 (0.9466–1.2007) | 0.298 |
| Clindamycin | 1.0827 (0.9902–1.1837) | 0.081 | 1.0716 (0.9540–1.2035) | 0.242 |
| Quinolones | 1.0268 (0.9121–1.1562) | 0.663 | 0.9873 (0.8478–1.1504) | 0.869 |
Adjusted models are adjusted for financial year, health board, percentage of patients aged ≥65 years, social deprivation score (percentage of registered patients living in the most deprived areas), PPI (per 1000 items per 1000 registered patients) and percentage of patients with COPD, diabetes and hypertension.